HER2 IHC3+ ADVANCED COLORECTAL CANCER

Clinical trials for HER2 IHC3+ ADVANCED COLORECTAL CANCER explained in plain language.

Never miss a new study

Get alerted when new HER2 IHC3+ ADVANCED COLORECTAL CANCER trials appear

Sign up with your email to follow new studies for HER2 IHC3+ ADVANCED COLORECTAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for Tough-to-Treat colon cancer patients

Disease control Not yet recruiting

This study is testing a new drug, TQB2102, for people with advanced colorectal cancer that has a specific marker called HER2 IHC3+ and has stopped responding to standard treatments. About 142 participants will be randomly assigned to receive either the new drug or a treatment cho…

Matched conditions: HER2 IHC3+ ADVANCED COLORECTAL CANCER

Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Mar 27, 2026 12:38 UTC

HER2 IHC3+ ADVANCED COLORECTAL CANCER

Get alerted when new HER2 IHC3+ ADVANCED COLORECTAL CANCER trials appear

New hope for Tough-to-Treat colon cancer patients